Business Context and Reporting Period
This Form 8-K is filed by Galecto, Inc. (not Damora Therapeutics, Inc.) with a report date of December 31, 2025. The filing discloses unregistered sales of equity securities and the appointment of a new Chief Operating Officer.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to specific transaction terms:
- Warrant Exercise Price: $23.01 per share (closing price on December 31, 2025).
- New Executive Base Salary: $540,000 annually.
- New Executive Target Bonus: 40% of base salary.
Material Changes
Unregistered Sale of Equity Securities (Item 3.02)
On December 31, 2025, the Company issued a warrant to Paramora Holding LLC to purchase up to 628,302 shares of common stock. The warrant has a 10-year expiration and was issued under Section 4(a)(2) of the Securities Act of 1933.
Executive Appointment (Item 5.02)
The Board appointed Sherwin Sattarzadeh as Chief Operating Officer, effective January 5, 2026. His compensation package includes:
- Equity Grants: 190,376 Restricted Stock Units (RSUs) vesting over four years and options to purchase 444,209 shares vesting over four years.
- Severance: 12 months of base salary for termination without cause; 18 months of base salary plus accelerated equity vesting in the event of a sale event.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the reliance on the Section 4(a)(2) exemption for the warrant issuance to an accredited investor.
Investor Verification Checklist
- Verify the exact terms of the Paramora Warrant in Exhibit 4.1, including any conditions precedent or restrictions.
- Review the full Offer Letter for Sherwin Sattarzadeh (Exhibit 10.1) to confirm specific vesting schedules and performance conditions.
- Confirm the impact of the new warrant issuance on the Company's fully diluted share count.
- Assess the strategic fit of Mr. Sattarzadeh's background in hematology/oncology with Galecto's current pipeline.